Nishadil
Signup Signin
Delhi | 25°C (windy)
Game-Changing Partnership: Hanmi Pharmaceutical's Oral Delivery Platform Licensed to Gilead Sciences

Game-Changing Partnership: Hanmi Pharmaceutical's Oral Delivery Platform Licensed to Gilead Sciences
Soaring Horizons: Cystic Fibrosis Therapeutics Market Set to Skyrocket to $39.15 Billion by 2034

Soaring Horizons: Cystic Fibrosis Therapeutics Market Set to Skyrocket to $39.15 Billion by 2034
Lupin's Latest Triumph: US FDA Greenlight for HIV Drug Ignites Stock Rally

Lupin's Latest Triumph: US FDA Greenlight for HIV Drug Ignites Stock Rally
A New Dawn: Revolutionary Long-Acting HIV Prevention Jab Set for Global Reach by 2027

A New Dawn: Revolutionary Long-Acting HIV Prevention Jab Set for Global Reach by 2027
Gilead Taps Veeva Vault CRM for Global Commercial Transformation

Gilead Taps Veeva Vault CRM for Global Commercial Transformation
Xilio Therapeutics Soars 8% on Groundbreaking Cancer Drug Data and Strategic Gilead Investment

Xilio Therapeutics Soars 8% on Groundbreaking Cancer Drug Data and Strategic Gilead Investment
Gilead's Visionary Expansion: Foster City Emerges as a Global Biotech Epicenter

Gilead's Visionary Expansion: Foster City Emerges as a Global Biotech Epicenter
Gilead Sciences Pioneers Future of Manufacturing with New California Development Site

Gilead Sciences Pioneers Future of Manufacturing with New California Development Site
Healthcare's Pulse Check: Why High-Yield Dividends Might Be Your Best Bet in a Struggling Sector

Healthcare's Pulse Check: Why High-Yield Dividends Might Be Your Best Bet in a Struggling Sector
A New Dawn in Oncology: Kite Pharma's $350 Million Acquisition of Interius Biotherapeutics Set to Revolutionize CAR T-Cell Therapy

A New Dawn in Oncology: Kite Pharma's $350 Million Acquisition of Interius Biotherapeutics Set to Revolutionize CAR T-Cell Therapy
Load more..